Actively Recruiting
Phase II Study of Sintilimab and Bevacizumab Biosimilar as Pre-Surgery Treatment for Resectable Liver Cancer Beyond Milan Criteria
Led by Sun Yat-sen University · Updated on 2026-01-16
37
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating neoadjuvant therapy using sintilimab combined with a bevacizumab biosimilar in patients with resectable hepatocellular carcinoma HCC beyond the Milan criteria. Surgical removal is the preferred treatment for HCC, but recurrence rates remain high. This phase II, single-arm study aims to assess whether this combined therapy before surgery can reduce recurrence risk and improve survival, building on prior success of this drug combination in advanced HCC cases. Participants will receive sintilimab at 200 mg intravenously every three weeks for three cycles and a bevacizumab biosimilar at 15 mgkg intravenously every three weeks for two cycles as neoadjuvant treatment. The therapy is given prior to surgery to evaluate its effect on tumor progression and recurrence. This study does not include a control group and focuses on this investigational drug regimen. During the study, participants will be closely monitored for recurrence-free survival and adverse events for up to two years. Researchers will also assess surgical outcomes such as the rate of complete tumor removal and pathological responses. Evaluations include safety monitoring and follow-ups to track overall survival and time to recurrence. The total observation period spans up to two years after treatment initiation.
CONDITIONS
Brief Title
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here